Showing results (31-40 of 142) with videos related to

Sort By:
Pageof 15
Biochemical Pharmacology|September 1, 1986
Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokineticsA Seago, P E Goss, L J Griggs, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 3, 2001
Synthesis of certain 2'-deoxyuridine derivatives containing substituted phenoxy groups attached to C-5'; evaluation as potential dUTP analoguesJ H Marriott, G W Aherne, A Hardcastle, et al.
Journal of Steroid Biochemistry|February 1, 1986
Metabolism of 4-hydroxyandrost-4-ene-3,17-dione by rat hepatocytesA B Foster, M Jarman, J Mann, et al.
Journal of Medicinal Chemistry|June 23, 1995
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancerG A Potter, S E Barrie, M Jarman, et al.
Biochemical Pharmacology|January 24, 1997
Antagonism of estrogen receptor and calmodulin association by antiestrogens is not dependent on an interaction with calmodulinM G Rowlands, R Grimshaw, M Jarman, et al.
British Journal of Cancer|September 1, 1994
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell linesS Y Sharp, M G Rowlands, M Jarman, et al.
Journal of Steroid Biochemistry|February 1, 1986
Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the ratP E Goss, M Jarman, J R Wilkinson, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 1, 1991
Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinomaT R Evans, M G Rowlands, M Jarman, et al.
Lancet (London, England)|September 27, 1980
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinomaB M Bryant, M Jarman, H T Ford, et al.
Cancer Chemotherapy and Pharmacology|March 6, 1998
Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell linesL Jin, N Legros, G Leclercq, et al.
Pageof 15